Imugene Reports Quarterly Activities and Cash Flows
Key points
- Promising initial data in the Concurrent BTKi Cohort of azer-cel Phase 1b Trial
- FDA grants Fast Track Designation for azer-cel in two additional indications
- Board strengthened with appointment of two new non-executive directors
- Post 30 June, $11.12 million raised from sophisticated, professional and institutional investors
- CEO resignation and search for new leadership underway
Full summary
Imugene Limited (ASX: IMU) has released its Quarterly Activities and Cash Flow report for the quarter ended 30 June 2026. The report highlights promising initial data from the Concurrent BTKi Cohort of the azer-cel Phase 1b trial, with complete and partial responses reported. The FDA granted Fast Track Designation for azer-cel in two additional indications: relapsed or refractory Chronic Lymphocytic Leukaemia / Small Lymphocytic Lymphoma (CLL/SLL) and Marginal Zone Lymphoma (MZL). The company also announced the appointment of two new non-executive directors to its board. Post quarter-end, Imugene completed a $11.12 million capital raise through a two-tranche placement. Additionally, the company announced the resignation of its CEO, Leslie Chong, and has initiated a search for new leadership.
Summary generated by a large language model. Please interpret with care.